Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma

Figure 1

Comprehensive gene expression analysis associated with IDH1 mutations in PRAD. (a) Percentage of prostate cancer types in cBioPortal data set of 9329 patients. (b) The locus enrichment map uses red dots to mark the motifs on each chromosome in PRAD. (c) Waterfall plot of the top 30 mutated genes in PRAD, with bars indicating the proportion of mutations per patient. (d and e) Volcano and scatter plots showing the frequency of mutation-associated gene changes in IDH1 in PRAD. (f) IDH1 protein structure showing the location of specific mutations. (g) Box marks of the most frequently altered genes in PRAD. (h) Association between IDH1 mutations and survival in PRAD. (i) Distribution and correlation of CNV in prostate cancer are marked in three color to visualize the distribution of CNV ratios.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)